АДИПОКИНЫ И КАРДИОМЕТАБОЛИЧЕСКИЙ СИНДРОМ
https://doi.org/10.18705/1607-419X-2014-20-5-422-432
Аннотация
Ожирение является одной из наиболее важных проблем общественного здравоохранения XXI века. В настоящее время жировая ткань рассматривается как активный эндокринный орган, производящий гормоны — адипокины. Адипокины являются одними из регуляторов чувствительности к инсулину, оксидативного стресса, энергетического обмена, свертываемости крови и воспалительных реакций. Именно поэтому адипокины могут являться реализаторами механизма негативного действия ожирения на сердечно-сосудистую систему. Изучение их патофизиологической роли может сделать адипокины терапевтической мишенью в борьбе с ожирением и ассоциированных с ним состояний.
Об авторах
М. А. Бояринова
Федеральный медицинский исследовательский центр имени В.А. Алмазова, Санкт-Петербург
Россия
Аспирант, научный сотрудник НИЛ «Эпидемиология артериальной гипертензии» НИО артериальной гипертензии ФМИЦ им. В.А. Алмазова
Россия
Аспирант, научный сотрудник НИЛ «Эпидемиология артериальной гипертензии» НИО артериальной гипертензии ФМИЦ им. В.А. Алмазова
О. П. Ротарь
Федеральный медицинский исследовательский центр имени В.А. Алмазова, Санкт-Петербург
Россия
Кандидат медицинских наук, заведующая НИЛ «Эпидемиология артериальной гипертензии» НИО артериальной гипертензии ФМИЦ им. В.А. Алмазова �
Россия
Кандидат медицинских наук, заведующая НИЛ «Эпидемиология артериальной гипертензии» НИО артериальной гипертензии ФМИЦ им. В.А. Алмазова �
А. О. Конради
Федеральный медицинский исследовательский центр имени В.А. Алмазова, Санкт-Петербург
Россия
Доктор медицинских наук, профессор, заместитель директора по научной работе ФМИЦ им. В.А. Алмазова», руководитель НИО артериальной гипертензии ФМИЦ им. В.А. Алмазова
Россия
Доктор медицинских наук, профессор, заместитель директора по научной работе ФМИЦ им. В.А. Алмазова», руководитель НИО артериальной гипертензии ФМИЦ им. В.А. Алмазова
Список литературы
1. Alberti K.G.M.M., Eckel R.H., Grundy S.M. et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; World heart federation; International atherosclerosis society; And international association for the study of obesity // Circulation. — 2009. — Vol. 120, № 16. — P. 1640–1645.
2. Alberti K.G.M.M., Zimmet P. The metabolic syndrome — a new worldwide definition // Lancet. — 2005. — Vol. 366, № 9491. — P. 1059–1062.
3. Halberg N., Wernstedt-Asterholm I., Scherer P.E. The adipocyte as an endocrine cell // Endocrinol. Metab. Clin. North America. — 2008. — Vol. 37, № 3. — P. 753–768.
4. Hsieh C.J., Wang P.W., Chen T.Y. The relationship between regional abdominal fat distribution and both insulin resistance and
5. subclinical chronic inflammation in non-diabetic adults // Diabetol. Metab. Syndr. — 2014. — Vol. 6, № 1. — P. 49.
6. Saleem U., Khaleghi M., Morgenthaler N.G. et al. Plasma carboxy-terminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome // J. Clin. Endocrinol. Metab. — 2009. — Vol. 94, № 7. — P. 2558–2564.
7. Tsimikas S., Willeit J., Knoflach M. et al. Lipoproteinassociated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study // Eur. Heart J. — 2009. — Vol. 30, № 1. — P. 107–115.
8. Jacobs M., Van Greevenbroek M.M.J., Van Der Kallen C.J.H. et al. Low-grade inflammation can partly explain the association between the metabolic syndrome and either coronary artery disease
9. or severity of peripheral arterial disease: the CODAM study // Eur. J. Clin. Invest. — 2009. — Vol. 39, № 6. — P. 437–444.
10. Cinti S., Mitchell G., Barbatelli G. et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans // J. Lipid Res. — 2005. — Vol. 46, № 11. — P. 2347–2355.
11. Lau D.C.W., Dhillon B., Yan H. et al. Adipokines: molecular links between obesity and atheroslcerosis // Am. J. Physiol. Heart Circulat. Physiol. — 2005. — Vol. 288, № 5. — P. 2031–2041.
12. Trayhurn P., Wood I.S. Adipokines: inflammation and the pleiotropic role of white adipose tissue // Br. J. Nutr. — 2004. — Vol. 92, № 3. — P.347–355.
13. Kobayashi H., Ouchi N., Kihara S. et al. Selective sup-pression of endothelial cell apoptosis by the high molecular weight form of adiponectin // Circ. Res. — 2004. — Vol. 94, № 4. — P. 27–31.
14. Hirose H. Serum high-molecular-weight adiponectin as a marker for the evaluation and care of subjects with metabolic syndrome and related disorders // J. Atheroscl. Thromb. — 2010. — Vol. 17, № 12. — P. 1201–1211.
15. Беляева О.Д., Баженова Е.А., Березина А.В. и др. Уровень адипонектина, показатели липидного и углеводного обменов у пациентов с абдоминальным ожирением // Арте-
16. риальная гипертензия. — 2009. — Т. 15, № 3. — С. 309-313. / Belyaeva O.D., Bazhenova E.A., Berezina A.V. et al. Adiponectin levels, lipid and carbohydrate metabolism in patients with abdomi-
17. nal obesity // Arterial Hypertension [Arterialnaya Gipertenziya]. — 2009. — Vol. 15, № 3. — P. 309–313 [Russian].
18. Wynne K., Stanley S., McGowan B. Appetite control // J. Endocrinol. — 2005. — Vol. 184, № 2. — P. 291–318.
19. Uotani S., Bjorbaek C., Tornoe J., Flier J.S. Functional properties of leptin receptor isoforms: internalization and degra dation of leptin and ligand-induced receptor downregulation // Diabetes. — 1999. — Vol. 48, № 2. — P. 279–286.
20. Gao S., Kinzig K.P., Aja S. et al. Leptin activates hypothalamic acetyl-Co Acarboxylase to inhibit food intake // Proc. Natl. Acad. Sci. USA. — 2007. — Vol. 104, № 44. — P. 17358–17363.
21. Hutley L., Prins J.B. Fat as an endocrine organ: relationship to the metabolic syndrome // Am. J. Med. Sci. — 2005. — Vol. 330, № 6. — P. 280–289.
22. Чубенко Е.А., Беляева О.Д., Беркович О.А. и др. Значение лептина в формировании метаболического синдрома // Проблемы женского здоровья. — 2010. — T. 5, № 1. — С. 45–56. /
23. Chubenko E.A., Belyaeva O.D., Berkovich O.A. et al. Meaning of leptin in the formation of the metabolic syndrome // Problems of Women’s Health [Problemy Zhenskogo Zdorovia]. — 2010. — Vol. 5, № 1. — Р. 45–56 [Russian].
24. Considine R.V., Sinha M.K., Heiman M.L. et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans // N. Engl. J. Med. — 1996. — Vol. 334, № 5. — P. 292–295.
25. Tschöp M., Wawarta R., Riepl R.L. et al. Post-prandial decrease of circulating human ghrelin levels // J. Endocrinol. Invest. — 2001. — Vol. 24, № 6. — P. 19–21.
26. Tschöp M., Weyer C., Tataranni P.A. et al. Circulating Ghrelin levels are decreased in human obesity // Diabetes. — 2001. — Vol. 50, № 4. — P. 707–709.
27. Stepien M., Rosniak-Bak K., Paradowski M. et al. Waist circumference, ghrelin and selected adipose tissue-derived adipokines as predictors of insulin resistance in obese patients: preliminary results // Med. Sci. Monit. — 2011. — Vol. 17, № 11. — P. 13–18.
28. Cowley M.A., Smith R.G., Diano S. et al. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis // Neuron. — 2003. — Vol. 37, № 4. — P. 649–661.
29. Oliver P., Picó C., Serra F. et al. Resistin expression in different adipose tissue depots during rat development // Mol. Cell Biochem. — 2003. — Vol. 252, № 1–2. — P. 397–400.
30. Patel L., Buckels A.C., Kinghorn I.J. et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators // Biochem. Biophys. Res. Commun. — 2003. — Vol. 300, № 2. — P. 472–476.
31. Savage D.B., Sewter C.P., Klenk E.S. et al. S. Resistin / Fizz3 expression in relation to obesity and peroxisome proliferatoractivated receptor-gamma action in humans // Diabetes. — 2001. — Vol. 50, № 10. — P. 2199–2202.
32. Lee J.H., Chan J.L., Yiannakouris N. et al. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulinresistant, and diabetic subjects // J. Clin. Endocrinol. Metab. — 2003. — Vol. 88, № 10. — P. 4848–4856.
33. Jain S.H., Massaro J.M., Hoffmann U. et al. Cross-sectional associations between abdominal and thoracic adipose tissue compartments and adiponectin and resistin in the Framingham Heart Study // Diabetes Care. — 2009. — Vol. 32, № 5. — P. 903–908.
34. Berndt J., Kloting N., Kralisch S. et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans // Diabetes. — 2005. — Vol. 54, № 10. — P. 2911–2916.
35. Curat C.A., Wegner V., Sengen`es C. et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin // Diabetologia. — 2006. — Vol. 49, № 4. — P. 744–747.
36. Pagano C., Pilon C., Olivieri M. et al. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans // J. Clin. Endocrinol. Metab. — 2006. — Vol. 91, № 8. — P. 3165–3170.
37. Haider D.G., Holzer G., Schaller G. et al. The adipokine visfatin is markedly elevated in obese children // J. Pediatr. Gastroenterol. Nutr. — 2006. — Vol. 43, № 4. — P. 548–549.
38. Zahorska-Markiewicz B., Olszanecka-Glinianowicz M., Janowska J. et al. Serum concentration of visfatin in obese women // Metabolism. — 2007. — Vol. 56, № 8. — P. 1131–1134.
39. Jin H., Jiang B., Tang J. et al. Serum visfatin concentrations in obese adolescents and its correlation with age and high-density lipoprotein cholesterol // Diabetes Res. Clin Pract. — 2008. — Vol. 79, № 3. — P. 412–418.
40. Michalska M., Iwan-Ziętek I., Gniłka W. PAI-1 and α2-AP in patients with morbid obesity // Adv. Clin. Exp. Med. — 2013. — Vol. 22, № 6. — P. 801–807.
41. Natali A., Toschi E., Baldeweg S. et al. Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes // Diabetes. — 2006. — Vol. 55, № 4. — P. 1133–1140.
42. Ma L.J., Mao S.L., Taylor K.L. et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1 // Diabetes. — 2004. — Vol. 53, № 2. — P. 336–346.
43. Schaefer K., Fujisawa K., Konstantinides S., Loskutoff D.J. Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice // FASEB J. — 2001. — Vol. 15, № 10. — P. 1840–1842.
44. Eckel R.H., Grundy S.M., Zimmet P.Z. The metabolic syndrome // Lancet. — 2005. — Vol. 365, № 9468. — P. 1415–1428.
45. Ianniello F., Quagliozzi L., Caruso A., Paradisi G. Low adiponectin in overweight/obese women:association with diabetes during pregnancy // Eur. Rev. Med. Pharmacol. Sci. — 2013. — Vol. 17, № 23. — P. 3197–3205.
46. Mojiminiyi O.A., Abdella N.A. Associations of resistin with inflammation and insulin resistance in patients with type 2 diabetes mellitus // Scand. J. Clin. Lab. Invest. — 2007. — Vol. 67, № 2. — P. 215–225.
47. Monteiro M.P. Anti-ghrelin vaccine for obesity: a feasible alternative to dieting? // Expert Rev. Vaccines. — 2011. — Vol. 10, № 10. — P. 1363–1365.
48. Gauna C., Meyler F.M., Janssen J.A. et al. Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity // J. Clin. Endocrinol. Metab. — 2004. — Vol. 89, № 10. — P. 5035–5042.
49. Broglio F., Prodam F., Riganti F. et al. The continuous infusion of acylated ghrelin enhances growth hormone secretion and worsens glucose metabolism in humans // J. Endocrinol. Invest. — 2008. — Vol. 31, № 9. — P. 788–794.
50. Steppan C.M., Bailey S.T., Bhat S. The hormone resistin links obesity to diabetes // Nature. — 2001. — Vol. 409, № 6818. — P. 307–312.
51. Walcher D., Hess K., Berger R. et al. Resistin: a newly identified chemokine for humanCD4-positivelymphocytes // Cardiovasc. Res. — 2010. — Vol. 85, № 1. — P. 167–174.
52. Morash B.A., Willkinson D., Ur E. et al. Resistin expression and regulation in mouse pituitary // FEBS Lett. — 2002. — Vol. 526, № 1–3. — P. 26–30.
53. Qatanani M., Szwergold N.R., Greaves D.R. et al. Macrophage-derived human resistin exacerbates adipose tissue inflammation and insulin resistance in mice // J. Clin. Invest. — 2009. — Vol. 119, № 3. — P. 531–539.
54. Chen B.H., Song Y., Ding E.L. et al. Circulating levels of resistin and risk of type 2 diabetes in men and women: results from two prospective cohorts // Diabetes Care. — 2009. — Vol. 32, № 2. — P. 329–334.
55. Schwartz D.R., Lazar M.A. Human resistin: found in translation from mouse to man // Trends Endocrinol. Metab. — 2011. — Vol. 22, № 7. — P. 259–265.
56. Fukuhara A., Matsuda M., Nishizawa M. et al. Visfatin: a protein secreted by visceral fat that Mimics the effects of insulin // Science. — 2005. — Vol. 307, № 5708. — P. 426–430.
57. Fukuhara A., Matsuda M., Nishizawa M. et al. Retraction // Science. — 2007. — Vol. 318, № 5850. — P. 565.
58. Brown J.E., Onyango D.J., Ramanjaneya M. et al. Visfatin regulates insulin secretion, insulin receptor signalling and mRNA expression of diabetes-related genes in mouse pancreatic β-cells // J. Mol. Endocrinol. — 2010. — Vol. 44, № 3. — P. 171–178.
59. Cheng Q., Dong W., Qian L. et al. Visfatin inhibits apoptosis of pancreatic β-cell line, MIN6, via the mitogen-activated protein kinase/phosphoinositide 3-kinase pathway // J. Mol. Endocrinol. — 2011. — Vol. 47, № 1. — P. 13–21.
60. Festa A., D’Agostino R. Jr., Mykkänen L. et al. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance // Arterioscler. Thromb. Vasc. Biol. — 1999. — Vol. 19, № 3. —
61. P. 562–568.
62. Festa A., Williams K., Tracy R.P. et al. Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes // Circulation. — 2006. — Vol. 113, № 14. — P. 1753–1759.
63. Landsberg L., Aronne L.J., Beilin L.J. et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of The Obesity Society and the American Society
64. of Hypertension // J. Clin. Hypertens. (Greenwich). — 2013. — Vol. 15, № 1. — P. 14–33.
65. Kazumi T., Kawaguchi A., Sakai K. et al. Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure // Diabetes Care. — 2002. — Vol. 25, № 6. — P. 971–976.
66. Allison M.A., Ix J.H., Morgan C. et al. Higher leptin is associated with hypertension: the Multi-Ethnic Study of Athero-sclerosis // J. Hum. Hypertens. — 2013. — Vol. 27, № 10. — P. 617–622.
67. Vadacca M. Leptin, adiponectin and vascular stiffness parameters in women with systemic lupus erythematosus // Intern. Emerg. Med. — 2013. — Vol. 8, № 8. — P. 705–712.
68. Carlyle M., Jones O.B., Kuo J.J. et al. Chronic cardiovascular and renal actions of leptin: role of adrenergic activity // Hypertension. — 2002. — Vol. 39, № 2. — P. 496–501.
69. Eikelis N., Schlaich M., Aggarwal A. et. al. Interactions between leptin and the human sympathetic nervous system // Hypertension. — 2003. — Vol. 41, № 5. — P. 1072–1079.
70. Shirasaka T., Takasaki M., Kannan H. Cardiovascular effects of leptin and orexins // Am. J. Physiol.-Regulatory Integrative Comparative Physiol. — 2003. — Vol. 284, № 3. — P. 639–651.
71. Singhal A., Farooqi I.S., Cole T.J. et al. Influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease? // Circulation. — 2002. — Vol. 106, № 15. —
72. P. 1919–1924.
73. Matsumura K., Tsuchihashi T., Fujii K., Abe I., Iida M. Central ghrelin modulates sympathetic activity in conscious rabbits // Hypertension. — 2002. — Vol. 40, № 5. — P. 694–699.
74. Iglesias M.J., Pineiro R., Blanco M. et al. Growth hormone releasing peptide (ghrelin) is synthesized and secreted by cardiomyocytes // Cardiovasc. Res. — 2004. — Vol. 62, № 3. — P. 481–488.
75. Rodrıguez A., Gomez-Ambrosi J., Catalan V. et al. Association of plasma acylated ghrelin with blood pressure and left ventricular mass in patients with metabolic syndrome // J. Hypertens. — 2010. — Vol. 28, № 3. — P. 560–567.
76. Ukkola O., Paakko T., Kesaniemi Y.A. Ghrelin and its promoter variant associated with cardiac hypertrophy // J. Hum. Hypertens. — 2012. — Vol. 26, № 7. — P. 452–457.
77. Vallejo S., Romacho T., Angulo J. et al. Visfatin impairs endothelium-dependent relaxation in rat and human mesenteric microvessels through nicotinamide phosphoribosyltransferase activity // PLoS One. — 2011. — Vol. 6, № 11. — e27299.
78. Zhang L., Curhan G.C., Forman J.P. Plasma resistin levels associate with risk for hypertension among nondiabetic women // J. Am. Soc. Nephrol. — 2010. — Vol. 21, № 7. — P. 1185–1191.
79. Smits M.M., Woudstra P., Utzschneider K.M. et al. Adipocytokines as features of the metabolic syndrome determined using confirmatory factor analysis // Ann. Epidemiol. — 2013. — Vol. 23,
80. № 7. — P. 415–421.
81. Karasek D., Vaverkova H., Halenka M. et al. Prehypertension in dyslipidemic individuals; relationship to metabolic parameters and intima-media thickness // Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. — 2013. — Vol. 157, № 1. — P. 41–49.
82. Sakamoto M., Suzuki H., Hayashi T. et al. Effects of candesartan in hypertensive patients with type 2 diabetes mellitus on inflammatory parameters and their relationship to pulse pressure // Cardiovasc. Diabetol. — 2012. — Vol. 11. — P. 118.
83. Kim K.N., Kim K.M., Kim B.T. et al. Relationship of plasminogen activator inhibitor 1 gene 4G/5G polymorphisms to hypertension in Korean women // Chin. Med. J. (Engl). — 2012. — Vol. 125, № 7. — P. 1249–1253.
84. Matsuzawa Y., Funahashi T., Kihara S. et al. Adiponectin and metabolic syndrome // Arterioscl. Thromb. Vasc. Biol. — 2004. — Vol. 24, № 1. — P. 29–33.
85. Xydakis A.M., Case C.C., Jones P.H. et al. Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight lose through caloric restriction // J. Clin. Endocrinol. Metab. — 2004. — Vol. 89, № 6. — P. 2697–2703.
86. Lee H.-S., Lee M., Joung H. Adiponectin represents an independent risk factor for hypertension in middle aged Korean women // Asia Pacific J. Clin. Nutrition. — 2007. — Vol. 16, № 1. — P. 10–15.
87. Pala L., Monami M., Ciani S. et al. Adipokines as possible new predictors of cardiovascular diseases: a case control study // J. Nutr. Metab. — 2012. — Vol. 2012. — Р. 253428. — doi: 10.1155/2012/253428
88. Wu Z.J., Cheng Y.J., Gu W.J., Aung L.H. Adiponectin is associated with increased mortality in patients with already established cardiovascular disease: A systematic review and metaanalysis // Metab. Clin. Experiment. — 2014. — Vol. 63, № 9. — P. 1157–1166.
89. Cooke J.P., Oka R.K. Does leptin cause vascular disease? // Circulation. — 2002. — Vol. 106, № 15. — P. 1904–1905.81. Park H.Y., Kwon H.M., Lim H.J. et al. Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro // Exp. Mol. Med. — 2001. — Vol. 33, № 2. — P. 95–102.
90. Artwohl M., Roden M., Holzenbein T. et al. Modulation by leptin of proliferation and apoptosis in vascular endothelial cells // Int. J. Obes. Relat. Metab. Disord. — 2002. — Vol. 26, № 4. — P. 577–580.
91. O’Rourke L., Gronning L.M., Yeaman S.J., Shepherd P.R. Glucose-dependent regulation of cholesterol ester metabolism in macrophages by insulin and leptin // J. Biol. Chem. — 2002. — Vol. 277, № 45. — P. 42557–42562.
92. Sierra-Honigmann M.R., Nath A.K., Murakami C. et al. Biological action of leptin as an angiogenic factor // Science. — 1998. — Vol. 281, № 5383. — P. 1683–1386.
93. Van Dielen F.M.H., Van’t Veer C., Schols A.M. et al. Increased leptin concentrations correlate with increased concentrations of inflammatory markers in morbidly obese individuals // Intern. J. Obes. — 2001. — Vol. 25, № 12. — P. 1759–1766.
94. Konstantinides S., Schafer K., Koschnick S., Loskutoff D.J. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity // J. Clin. Invest. — 2001. — Vol. 108, № 10. — P. 1533–1540.
95. Tesauro M., Schinzari F., Iantorno M. et al. Ghrelin improves endothelial function in patients with metabolic syndrome // Circulation. — 2005. — Vol. 112, № 19. — P. 2986–2992.
96. Li W.G., Gavrila D., Liu X. et al. Ghrelin inhibits proinflammatory responses and nuclear factor-kappaB activation in human endothelial cells // Circulation. — 2004. — Vol. 109, № 18. — P. 2221–2226.
97. Kawanami D., Maemura K., Takeda N. et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions // Biochem. Biophys. Res. Commun. — 2004. — Vol. 314, № 2. — P. 415–419.
98. Lee T.S., Lin C.Y., Tsai J.Y. et al. Resistin increases lipid accumulation by affecting class A scavenger receptor, CD36 and ATP-binding cassette transporter-A1 in macrophages // Life Sci. — 2009. — Vol. 84, № 3–4. — P. 97–104.
99. Piestrzeniewicz K., Łuczak K., Komorowski J. et al. Resistin increases with obesity and atherosclerotic risk factors in patients with myocardial infarction // Metabolism. — 2008. — Vol. 57,
100. № 4. — P. 488–493.
101. Choi H.Y., Kim S., Yang S.J. et al. Association of adiponectin, resistin, and vascular inflammation: analysis with 18F-fluorodeoxyglucose positron emission tomography // Arterioscler. Thromb. Vasc. Biol. — 2011. — Vol. 31, № 4. — P. 944–949.
102. Reilly M.P., Lehrke M., Wolfe M.L. et al. Resistin is an inflammatory marker of atherosclerosis in humans // Circulation. — 2005. — Vol. 111, № 7. — P. 932–939.
103. Ohmori R., Momiyama Y., Kato R. et al. Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease // J. Am. Coll. Cardiol. — 2005. — Vol. 46, № 2. — P. 379–380.
104. Wang H., Chen D.Y., Cao J. et al. High serum resistin level may be an indicator of the severity of coronary disease in acute coronary syndrome // Chin. Med. Sci. J. — 2009. — Vol. 24, № 3. — P. 161–166.
105. On Y.K., Park H.K., Hyon M.S., Jeon E.S. Serum resistin as a biological marker for coronary artery disease and restenosis in type 2 diabetic patients // Circ. J. — 2007. — Vol. 71, № 6. — P. 868–873.
106. Krecki R., Krzeminska-Pakula M., Peruga J.Z. et al. Elevated resistin opposed to adiponectin or angiogenin plasma levels as a strong, independent predictive factor for the occurrence of major
107. adverse cardiac and cerebrovascular events in patients with stable multivessel coronary artery disease over 1-year follow-up // Med. Sci. Monit. — 2011. — Vol. 17, № 1. — P. 26–32.
108. Momiyama Y., Ohmori R., Uto-Kondo H. et al. Serum resistin levels and cardiovascular events in patients undergoing percutaneous coronary intervention // J. Atheroscler. Thromb. — 2011. — Vol. 18, № 2. — P. 108–114.
109. Cabrera de León A., Almeida González D., González Hernández A. et al. The association of resistin with coronary disease in the general population // J. Atheroscler. Thromb. — 2014. — Vol. 21, № 3. — P. 273–281.
110. Vanhoutte P.M. Endothelial dysfunction: the first step toward coronary arteriosclerosis // Circul. J. — 2009. — Vol. 73, № 4. — P. 595–601.
111. Kong Q.X., Xia M., Liang R.Q. et al. Increased serum visfatin as a risk factor for atherosclerosis in patients with ischaemic cerebrovascular disease // Singapore Med. J. — 2014. — Vol. 55, № 7. — P. 383–387.
112. Dahl T.B., Yndestad A., Skjelland M. et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization // Circulation. — 2007. — Vol. 115, № 8. — P. 972–980.
113. Kim S.R., Bae S.K., Choi K.S. et al. Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase ½ // Biochem. Biophys. Res. Communications. — 2007. — Vol. 357, № 1. — P. 150–156.
114. Xiao J., Xiao Z.J., Liu Z.G. et al. Involvement of dimethylarginine dimethylaminohydrolase-2 in visfatin-enhanced angiogenic function of endothelial cells // Diabetes/Metab. Res. Rev. — 2009. — Vol. 25, № 3. — P. 242–249.
115. Moulton K.S. Angiogenesis in atherosclerosis: gathering evidence beyond speculation // Curr. Opin. Lipidol. — 2006. — Vol. 17, № 5. — P. 548–555.
116. Moschen A.R., Kaser A., Enrich B. et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties // J. Immunol. — 2007. — Vol. 178, № 3. — P. 1748–1758.
117. Kohler H.P., Grant P.J. Plasminogen-activator inhibitor type 1 and coronary artery disease // N. Engl. J. Med. — 2000. — Vol. 342, № 24. — P. 1792–1801.
118. Schneiderman J., Sawdey M.S., Keeton M.R. et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries // Proc. Natl. Acad. Sci. U S A. — 1992. — Vol. 89, № 15. — P. 6998–7002.
119. DePaoli A.M. 20 years of leptin: leptin in common obesity and associated disorders of metabolism // J. Endocrinol. — 2014. — Vol. 223, № 1. — P. 71–81.
120. Amylin Pharmaceuticals, Inc. Takeda Pharmaceutical Company Limited Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following Commercial Reassessment of the Program // Newsroom. — July-September, 2011.
121. Okada-Iwabu M., Yamauchi T., Iwabu M. et al. A smallmolecule AdipoR agonist for type 2 diabetes and short life in obesity // Nature. — 2013. — Vol. 503, № 7477. — P. 493–499.
122. Lu S.C., Xu J., Chinookoswong N. et al. An acyl-ghrelin-specific neutralizing antibody inhibits the acute ghrelin-mediated orexigenic effects in mice // Mol. Pharmacol. — 2009. — Vol. 75, № 4. — P. 901–907.
123. Mayorov A.V., Amara N., Chang J.Y. et al. Catalytic antibody degradation of ghrelin increases whole-body metabolic rate and reduces refeeding in fasting mice // Proc. Natl Acad. Sci. USA. — 2008. — Vol. 105, № 45. — P. 17487–17492.
124. Nagaya N., Moriya J., Yasumura Y. et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure // Circulation. — 2004. — Vol. 110, № 24. — P. 3674–3679.
125. Cummings D.E., Weigle D.S., Frayo R.S. et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery // N. Engl. J. Med. — 2002. — Vol. 346, № 21. — P. 1623–1630.
126. Alfadda A.A. Circulating adipokines in healthy versus unhealthy overweight and obese subjects // Int. J. Endocrinol. — 2014. — Vol. 2014. — Р. 170434. — doi: 10.1155/2014/170434
127. Aguilar-Salinas C., García E., Robles L. et al. High adiponectin concentrations are associated with the metabolically healthy obese phenotype // J. Clin. Endocrinol. Metab. — 2008. — Vol. 93, № 10. — P. 4075–4079.
128. Karelis A.D. Metabolically healthy but obese individuals // Lancet. — 2008. — Vol. 372, № 9646. — P. 1281–1283.
Рецензия
Для цитирования:
Бояринова М.А., Ротарь О.П., Конради А.О. АДИПОКИНЫ И КАРДИОМЕТАБОЛИЧЕСКИЙ СИНДРОМ. Артериальная гипертензия. 2014;20(5):422-432. https://doi.org/10.18705/1607-419X-2014-20-5-422-432
For citation:
Boyarinova M.A., Rotar O.P., Konradi A.O. ADIPOKINES AND CARDIOMETABOLIC SYNDROME. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2014;20(5):422-432. https://doi.org/10.18705/1607-419X-2014-20-5-422-432
Просмотров:
1445
Послать статью по эл. почте 